BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial.
暂无分享,去创建一个
M. Baccarani | M. Vignetti | G. Gaidano | M. Rondoni | G. Rosti | G. Martinelli | M. Breccia | G. Alimena | R. Bassan | L. Luciano | G. Gugliotta | F. Lauria | M. Trawinska | A. Gozzetti | M. Bocchia | M. Amabile | L. Cannella | D. Turri | M. Defina | F. Iuliano | A. Rossi | P. Nicoli | M. Ippoliti | L. Aprile